June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Evaluation of Cystoid Macular Edema and Inner-segment-outer-segment Span Loss in Predicting Visual Progression in Patients with Retinitis Pigmentosa
Author Affiliations & Notes
  • Alice Behrens
    Valley Retina Institute, McAllen, Texas, United States
  • AGUSTIN LORIA
    Valley Retina Institute, McAllen, Texas, United States
  • Walter I. Rivera
    Valley Retina Institute, McAllen, Texas, United States
  • Victor H Gonzalez
    Valley Retina Institute, McAllen, Texas, United States
  • Footnotes
    Commercial Relationships   Alice Behrens, None; AGUSTIN LORIA, None; Walter Rivera, None; Victor Gonzalez, Abbvie (C), Alimera (F), Allegro ophthalmics (F), Allergan (C), Astellas Institute of Regenerative Medicine (F), Bausch and Lomb (C), Bayer (C), Beaver-Visitec International (C), Boehringer Ingelheim (F), Clearside Biomedical (F), DRCR NET (F), Eyegate Pharma (F), Genetech (C), Graybug Vision Inc (F), Iconic Therapeutics (F), Insite Vision Inc. (F), Norvatis (C), Ophthea Ltd (F), Opternative (F), Panoptica (C), Regeneron (F), Santen (C), Thrombogenics Inc. (F), Topcon (C), Valcant (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3050. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alice Behrens, AGUSTIN LORIA, Walter I. Rivera, Victor H Gonzalez; Evaluation of Cystoid Macular Edema and Inner-segment-outer-segment Span Loss in Predicting Visual Progression in Patients with Retinitis Pigmentosa. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3050.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Many studies have focused on identifying and treating cystoid macular edema (CME) with or without retinal thinning, as well as using inner-segment-outer segment junction (IS/OS) loss to follow disease progression. Resolution of CME is correlated with improved vision. However, we postulate that the presence of CME during disease progression of RP is a positive prognostic indicator for better preservation of functional vision. We also evaluate the correlation of visual acuity, CME span and the span of IS/OS junction loss.

Methods : We identified patients with the diagnosis of retinitis pigmentosa without diabetic retinopathy, age related macular degeneration or any other retinal degeneration from 2009-2019, with a minimal of two office visits over at least 1 year of follow-up. Fourteen eyes with CME from 9 patients and 33 eyes from 19 patients without CME were retrospectively reviewed. Heidelberg optical coherent tomography (OCT) was used to measure the horizontal span of CME, central retinal thickness, and central horizontal span of IS/OS loss. Visual acuity progression (change of vision in LogMAR per year), IS/OS span loss on initial presentation were compared between the CME and non-CME groups.

Results : In this study, 36% were male patients; mean age were 33.4 years in the CME group and 42.6 years in the non-CME group. There were 53% and 12% phakic patients in the CME group and the non-CME group were phakic; no aphakia patients in either group. The mean LogMAR visual acuity on initial presentation for CME group and non-CME group were 0.344 (Snellen equivalence [SE] 20/44) and 0.95 (SE 20/179), respectively (p= 0.043, Mann-Whitney test). The mean decline of vision in LogMAR per year for the CME and non-CME groups were -0.034 and 0.033, respectively (p= 0.92, Mann-Whitney test). The mean initial spans of IS/OS loss for the CME and non-CME groups were 3133nm and 3473nm, respectively (p= 0.41, Mann-Whitney test). There is a positive association of IS/OS span loss and CME span (mean span of 313nm) but not statistically significant (r=0.12, p=0.33, Spearman’s Rho test).

Conclusions : The presence of CME is a positive indicator of visual acuity, but neither CRT or span of CME is reliable predictor of rate of vision loss. The initial span of IS/OS loss does not correlate with rate of visual acuity decline for either group.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×